Clinical Trials Directory

Trials / Completed

CompletedNCT05992116

Iron Deficiency in Patients With Heart Failure and Reduced and Mildly Reduced Ejection Fraction

The Prevalence of Iron Deficiency in Patients With Heart Failure (HFrEF and HFmrEF) in a Middle Eastern Population

Status
Completed
Phase
Study type
Observational
Enrollment
450 (actual)
Sponsor
Jordan Collaborating Cardiology Group · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers

Summary

A significant percentage of patients with heart failure and reduced ejection fraction (HFrEF) or mildly reduced ejection fraction (HFmrEF) have iron deficiency who are symptomatic. This is independently associated with bad quality of life, low functional capacity, lower quality of, life and increased mortality. The prevalence of iron deficiency in HFrEF and HFmrEF patients in Jordan has not been studied in the past.

Detailed description

The prevalence of chronic heart failure among the industrialized countries is 1-3%, and can exceed 30% in the elderly population. As the population ages, there is an increase in the number of co-morbidities among heart failure patients. These comorbidities are associated with an increase in major adverse cardiac events (MACE), cost, and complexity of care. Iron deficiency is one of the most common comorbidities occurring in patients with heart failure. Its prevalence can be as high as 59%, even if patients are non-anemic\[4\]. Iron deficiency in heart failure can lead to an impaired exercise capacity, a decreased quality of life and an increased risk of hospitalizations and mortality regardless of anemia. The relationship between the severity of iron deficiency and the prognosis is a linear one, with increased severity being associated with increased mortality. Intravenous iron treatment has been shown to improve the quality of life, with an increased exercise capacity and a reduced risk for hospitalizations. The prevalence of iron deficiency in HFrEF and HFmrEF patients in Middle Eastern population has not been studied. We suspect a higher prevalence compared to Western populations especially in women.

Conditions

Timeline

Start date
2023-09-01
Primary completion
2025-01-15
Completion
2025-02-22
First posted
2023-08-15
Last updated
2025-02-25

Locations

1 site across 1 country: Jordan

Source: ClinicalTrials.gov record NCT05992116. Inclusion in this directory is not an endorsement.